Novedades en el estadio III de CPNM

NCT03285321: Phase II Study of Consolidation Immunotherapy With Nivolumab and

Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081

• Unresectable, Stage IIIA-B

NSCLC without

progression after definitive

platinum-based

CONCURRENT CRT

• 18 years or older

• WHO PS score 0 or 1

• PD-L1 known

N:108

Nivolumab 480 mg c/4w

6 cycles

Nivolumab 3mg/kg c/2w

12 doses + IPI 1 mg/kg

c/6w 4 cycles

Key secondary

endpoint

• OS

• TTMD

• AEs

Primary endpoint

• PFS